Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study

PURPOSE: Cancer cells can exploit the programmed death-1 (PD-1) immune checkpoint pathway to avoid immune surveillance by modulating T-lymphocyte activity. In part, this may occur through overexpression of PD-1 and PD-1 pathway ligands (PD-L1 and PD-L2) in the tumor microenvironment. PD-1 blockade h...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Clin Oncol
Asıl Yazarlar: Lesokhin, Alexander M., Ansell, Stephen M., Armand, Philippe, Scott, Emma C., Halwani, Ahmad, Gutierrez, Martin, Millenson, Michael M., Cohen, Adam D., Schuster, Stephen J., Lebovic, Daniel, Dhodapkar, Madhav, Avigan, David, Chapuy, Bjoern, Ligon, Azra H., Freeman, Gordon J., Rodig, Scott J., Cattry, Deepika, Zhu, Lili, Grosso, Joseph F., Bradley Garelik, M. Brigid, Shipp, Margaret A., Borrello, Ivan, Timmerman, John
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Clinical Oncology 2016
Konular:
ORIGINAL REPORTS
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5019749/
https://ncbi.nlm.nih.gov/pubmed/27269947
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2015.65.9789
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller